FY2025 EPS Estimates for Biomea Fusion Cut by HC Wainwright

Biomea Fusion, Inc. (NASDAQ:BMEA) – Research analysts at HC Wainwright decreased their FY2025 earnings per share estimates for shares of Biomea Fusion in a research report issued on Tuesday, April 1st. HC Wainwright analyst J. Pantginis now expects that the company will earn ($3.91) per share for the year, down from their previous estimate of ($3.17). HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Biomea Fusion’s current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Biomea Fusion’s FY2026 earnings at ($3.56) EPS, FY2027 earnings at ($2.39) EPS and FY2028 earnings at ($2.45) EPS.

BMEA has been the subject of a number of other reports. Oppenheimer set a $10.00 price target on shares of Biomea Fusion in a research note on Monday, March 24th. Barclays cut their price target on Biomea Fusion from $11.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $16.00 price objective on shares of Biomea Fusion in a research note on Wednesday, March 19th. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $23.91.

Biomea Fusion Trading Up 8.5 %

Biomea Fusion stock opened at $2.16 on Thursday. The company has a market cap of $78.28 million, a PE ratio of -0.54 and a beta of -0.26. Biomea Fusion has a 1 year low of $1.87 and a 1 year high of $14.43. The company’s 50-day moving average is $3.19 and its two-hundred day moving average is $5.89.

Biomea Fusion (NASDAQ:BMEA) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.19.

Hedge Funds Weigh In On Biomea Fusion

Several institutional investors have recently modified their holdings of BMEA. Bayesian Capital Management LP acquired a new stake in Biomea Fusion during the 4th quarter worth approximately $42,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Biomea Fusion during the third quarter worth $111,000. Wells Fargo & Company MN lifted its position in Biomea Fusion by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 12,914 shares of the company’s stock valued at $50,000 after acquiring an additional 4,399 shares in the last quarter. Intech Investment Management LLC acquired a new position in Biomea Fusion in the 4th quarter worth $54,000. Finally, Maia Wealth LLC acquired a new stake in shares of Biomea Fusion in the 4th quarter valued at about $62,000. Institutional investors own 96.72% of the company’s stock.

Biomea Fusion Company Profile

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.